NASDAQ:SBOT - Stellar Biotechnologies Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$7.72
▼ -0.26 (-3.26%)
Get New Stellar Biotechnologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SBOT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SBOT

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Stellar Biotechnologies in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $7.72.

This chart shows the closing price for SBOT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Stellar Biotechnologies. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/2/2016Maxim GroupLower Price TargetBuy$49.00 ➝ $28.00N/A
(Data available from 10/27/2016 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/27/2021

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Stellar Biotechnologies logo
Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia. The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market. It provides its KLH protein under the Stellar KLH brand. The company's products include Stellar KLH protein in various grades, formulations, custom configurations, and fill finishes for drug development and research applications, as well as KLH-based in vitro diagnostic kits for research and preclinical use. Its customers and partners comprise biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California.
Read More

Today's Range

Now: $7.72
Low: $7.70
High: $7.97

50 Day Range

MA: $59,624.23
Low: $4.44
High: $298,098.00

52 Week Range

Now: $7.72
Low: $0.75
High: $3.25

Volume

277,528 shs

Average Volume

2,949,088 shs

Market Capitalization

$41.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Stellar Biotechnologies?

The following Wall Street analysts have issued research reports on Stellar Biotechnologies in the last year:
View the latest analyst ratings for SBOT.

What is the current price target for Stellar Biotechnologies?

0 Wall Street analysts have set twelve-month price targets for Stellar Biotechnologies in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Stellar Biotechnologies in the next year.
View the latest price targets for SBOT.

What is the current consensus analyst rating for Stellar Biotechnologies?

Stellar Biotechnologies currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SBOT.

What other companies compete with Stellar Biotechnologies?

How do I contact Stellar Biotechnologies' investor relations team?

Stellar Biotechnologies' physical mailing address is 332 EAST SCOTT STREET, PORT HUENEME CA, 93041. The biotechnology company's listed phone number is 805-488-2800 and its investor relations email address is [email protected] The official website for Stellar Biotechnologies is www.stellarbiotechnologies.com.